Use of Bone Scanning and Skeletal Radiography in the Diagnosis of Bone Metastasis by Mall, Jay C. & Hoffer, Paul B.
Use of Bone Scanning and Skeletal Radiography 
in the Diagnosis of Bone Metastasis 
JAY C. MALL, M .D . AND PAUL B. HOFFER, M .D . 
Department of Radiology, University of California Medical Center. San Francisco, California 
The radionuclide bone scan is becoming in-
creasingly useful for evaluating a wide variety of bone 
and joint disorders. However , the commonest ap-
plication is still the detection of skeletal metastases in 
the patient with known or suspected neoplastic dis-
ease. The role of this examination relative to other 
well established methods of evaluating these patients, 
especially the radiographic skeletal survey, is not 
clear to all physicians. We hope in this communica-
tion to define the role of the radionuclide bone scan 
and to place in perspective the integral relationship 
between the "scan" and the "survey," the two 
radiologic modalities whi_ch today are the principal 
methods of evaluating the skeletal system for 
metastatic disease. 
Radiopharmaceuticals. Historically, numerous 
agents have been used for bone scanning, but only a 
small number have been applicable for general 
clinical use. The first of these were the strontium 
isotopes , strontium-85 and strontium-87m . Subse-
quently, fl uorine-18 and, most recently, the 
technetium-99m-labeled phosphate compounds have 
been used . 
Strontium. Strontium is an analogue of calcium 
and, as such, is incorporated into the hydroxyapatite 
crystal by an ion-exchange process with calcium (I). 
Unfortunately, the plasma clearance of strontium is 
slow due to partial binding with plasma proteins (2, 
3). Excretion occurs by both urinary tract and bowel 
(4) . 
Strontium-85 nitrate was one of the first agents 
used for imaging of bone lesions. Its long physical 
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half-life of 65 days severely limited the administered 
dose, which was usually 100 microcuries. The pres-
ence of bowel activity in the first few days follow-
ing injection necessitated cleansing enemas and/or 
long delays between isotope administration and scan. 
Its 514 kev photon was also much higher than ideal 
for nuclear imaging instrumentation. Nevertheless, 
8 5Sr was a clinically useful bone scanning agent. 
Strontium-87m has a considerably shorter phys-
ical half-life (2 .8 hours) and lower photon energy (388 
kev) making it a physically more desirable agent. 
Unfortunately, the high body-background during the 
first 12 hours following injection results in less than 
optimal clinical images (2) and, therefore, this agent 
has not been widely used for bone imaging. 
Fluorine-18. Fluorine-18 is a hydroxyl analogue 
which is incorporated into bone by an ion-exchange 
process forming a fluorapatite crystal (I, 5). Bone has 
a very high affinity for fluorine with most of the 
radionuclide extracted from the blood on the initial 
transit (2, 5). The renal extraction efficiency is also 
high and, therefore, plasma clearance of 18F is the 
most rapid of any of the clinically useful bone scan-
ning radionuclides (6,7). Excellent bone-to-back-
ground . ratios can be obtained with 18F at . l to 2 
hours following intravenous injection (3, 6) . The half-
life is very short ( 1.8 hours) which is advantageous 
from the standpoint of patient dose. However, the 
short half-life of 18 F is also a problem because it is 
cyclotron-produced (8) and , therefore, its use is 
limited to those locations in close proximity to a 
cyclotron . The 511 kev annihilation radiation from 
18 F makes imaging with the gamma camera difficult. 
The best images are obtained with a rectilinear scan-
ner or special positron camera (5, 9). Transportation 
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problems and cost, both related to the short half-life 
of 18F , have inhibited its clinical use. 
Technetium-99m-labeled compounds. This group 
of compounds contains the phosphate polymers, 
pyrophosphate and polyphosphate, and their organic 
analogues, the diphosphonates. These agents localize 
Fig I- Decreased uptake in Ilium (arrow) in patient with 
metastatic bone lesion. Such "photopenic" lesions occur as a result 
of lack of hyperemic respo nse to tumor due to debilita tio n, fa ilu re 
o f tumo r to provoke response, or radia tion to region of lesio n. 
in bone crystal by surface chemisorption rather than 
ionic exchange (10,11). The terminal phosphate 
groups of the 99mTc-labeled compound react with the 
" phosphate gaps" which are present in the imperfect 
bone crystals. (The 99mTc acts only as a label unlike 
18F and the Sr isotopes) . Plasma clearance varies 
' 
Fig 2-Diffuse increase in skeleta l activity denoted by " a bsence" 
of rena l acti vity. In add iti on to di ffuse metastasis, the absent 
kidney sign may a lso be seen in severe renal disease, hyper-
parathyroidism a nd hypermetabo lic sta tes. 
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TABLE I 
Bone Scans vs. Skeletal Survey 
for the Detection of Metastatic Lesions to Bone 
Radionuclide 
No. of +scan -scan 
Source pts. 
-x-ray +x-ray 
Sr DeNardo (1966) 84 38% 4% 
DeNardo et al. (1972) 
Briggs (1967) 83 20% 1% 
Bessler ( 1968) 104 15% 1% 
Harmer et al. (1969) 47 41% 6% 
Legge et al. (1970) 186 13% 2% 
G nekow et al. ( 1972) 353 8% 2% 
18 Fl Harmer et al. ( 1969) 112 31% 3% 
Blau et al. ( 1972) 239 15% 4.5% 
Hopkins et al. (1972) 104 20% 4% 
Merrick ( 1973) 119 13% 0 
99mTc Desaul'1iers (1973) 100 9% 1% 
Pendergrass (1973) 259 20% 2% 
Citrin et al. (1974) 70 10% 0 
Barrett and Smith ( 1974) 90 71 % (of 2% 
lesions) 
among the principal agents comprising this group 
with the diphosphonates being cleared most rapidly, 
pyrophosphate cleared somewhat less rapidly, and 
polyphosphates being cleared least rapidly (7). The 
bone-to-background ratios achieved with the 
diphosphonates at 3 hours is a lmost comparable to 
TABLE 2 
Bone Scan vs. Skeletal Survey For Specific Tumor Types 
Source 
Breast 
Sklaroff and Charkes ( 1968) 
Galasko (1969) 
Galasko (1971) 
Marty and Hoffman (1972) 
Lung 
Sauerbrum et a l (1972) 
Shirazi et a l ( 1973) 
Prostate 
Morgan and Mills(l968) 
Williams et al (1968) 
Royetal(l971) 
Shearer et al (1974) 
Bisson et a l (1974) 
Lymphoma 
Weber et a l (1968) 
H arbert and Ashburn (1968) 
Moran et al ( 1973) 
+ scan - scan 
# ofpts. - x-ray + x-ray 
64 
100 
164 
82 
206 
66 
70 
30 
61 
81 
19 
51 
80 
16% 
29% 
26% 
30% 
7% 
42% 
2 1% 
53% 
12% 
27% 
74% 
12% 
5% 
0 
0 
0 
1% 
0 
0 
0 
1% 
1% 
0 
4% 
0 
that achieved with 18F at l to 2 hours (6, 7). Other ad-
vantages of this group of agents are the short half-life 
of 99mTc (6 hours) which permits the safe administra-
tion of millicurie doses and near optimal gamma 
energy (140 kev) and high photon flux which make 
possible rapid performance of the procedure and 
good spatial resolution with the gamma camera, the 
most widely used nuclear imaging device. The ready 
availability and easy preparation from commercial 
kits with a long shelf-life also make them ideal for 
general clinical use. The 99mTc-labeled compounds 
are the current agents of choice for bone scanning. 
The availability of these excellent and convenient 
agents has fostered the recent widespread clinical 
popularity of bone scanning. 
"Scans Signs" of Tumor. Considerable lab-
oratory data has accumulated over the past years 
indicating that the two principal factors involved in 
the uptake of bone-seeking radionuclides into the 
bone are I) bone blood flow and 2) metabolic activity 
of the bone ( I 0, 12, 13 ). Recent evidence has in-
dicated that for 18F and the 99mTc-labeled phosphate 
compounds, bone blood fl.ow is the most important 
factor ( I 0). 
The detection of metastatic tumor in bone is 
based on the premise that the destructive and 
reparative events that occur in the bone as a result of 
a metastatic deposit cause a localized increase in 
blood fl.ow and bone turnover. This in turn results in 
localized increased uptake of the bone scanning agent 
which is imaged as a "hot spot" on the bone scan. 
This "hot spot" can usually be easily recognized by 
an alteration in the bilateral symmetry or, as with 
the axial skeleton, an alteration of the homogeneous 
uptake in the spine. A second "scan sign" of tumor 
involvement is a localized area of decreased uptake of 
the bone scanning agent (Fig 1). This has been re-
ferred to as a "photon deficient" or "photopenic" ab-
normality and occurs in cases where there is replace-
ment of a portion of bone by tumor with little or no 
reparative response on the part of the host because of 
the nature of the tumor or the debilitated state of the 
patient (14 ). (Similar findings noted by R . S. Hatt-
ner, MD, unpublished data.) This is a distinctly less 
common sign of skeletal involvement than a localized 
area of increased uptake. A third "scan sign" of met-
astatic involvement of the skeleton is diffuse but uni-
form increased uptake which does not alter the bi-
lateral symmetry and may only be recognized by the 
decrease in renal activity (Fig 2) (15). Normally, the 
kidneys in adult patients can be clearly identified at 
MALL AND HOFFER: BONE SCANNING AND SKELETAL RADIOGRAPHY 111 
3 to 4 hours following administration of the 99mTc 
compounds. The absence of renal activity is a rare 
but important manifestation of metastatic skeletal in-
volvement which occurs when so much of the radio-
nuclide is deposited in bone that virtually none is 
available to be localized in the kidney. In some re-
ported series, this "scan sign" was unrecognized and 
such cases were termed false-negative ( 16, 17). 
Comparison of Bone Scan to Bone Survey. Many 
clinical studies have been performed comparing the 
relative sensitivity of the radionuclide bone scan and 
the radiographic skeletal survey for the detection of 
skeletal metastases. In earlier reports, 85Sr and 87mSr 
were the isotopes used for radionuclide bone scan-
ning, but in more recent reports 18F and 99mTc-labeled 
phosphate compounds have been employed. These 
studies are summarized in Table 1 (5, 18-28). All of 
these studies-indicate that the radionuclide bone scan 
is more sensitive than the radiographic skeletal sur-
vey for detecting skeletal metastases. Some reports 
indicate that the results with 99mTc-labeled phosphate 
compounds are even better than with 18F or the Sr 
agents (26-31 ). For certain common neoplasms, a 
particularly large experience has accrued over the 
years to compare the two techniques of bone scan-
ning and skeletal survey on a tumor-oriented basis. 
These comparisons are summarized in Table 2 (32-
45) and as noted by E. M. Moran, MD (oral 
communication, June, 1973). 
Although it is quite clear that the radionuclide 
bone scan is more sensitive than the radiographic 
skeletal survey for detecting skeletal metastases, it is 
important to remember that the examination is non-
specific in nature. Focal areas of increased 
radionuclide uptake in bone are invariably due to 
some skeletal abnormality; however, it must be noted 
that the scan can be "positive" in numerous condi-
tions other than neoplasm (Fig 3A and 38) (46, 47). 
Table 3 is a list of non-neoplastic conditions which 
cause focal increase in radionudide uptake in bone. 
The radiograph, on the other hand, while not as sen-
sitive, is quite specific and may exhibit characteristic 
patterns which allow for a more accurate etiologic 
diagnosis. For these reasons, a radiograph is always 
necessary to assess the significance of a scan abnor-
mality. 
False-negative radionuclide bone scans occur in-
frequently, in approximately 0.4% of patients in most 
of the recent studies as noted in Tables I and 2. These 
have been seen to occur in certain specific situa-
tions ( 17,48-50). They are: 1) Some patients with 
' 
Fig 3A - Abnormal bone scan revealing increased radionuclide 
uptake in the left clavicle and p rox imal right tibia. 
myeloma; 2) some patients with tumor of anaplastic 
cell type; 3) some severely debilitated patients with 
poor host response; 4) patients with diffuse disease 
uniformly involving the whole skeleton; 5) patients 
with pelvic lesions obscured by a high level of activity 
in the bladder; 6) lesions that have been irradiated. 
As to the incidence of false-positive bone scans, in 
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Fig 38-Radiograph of clavicle reveals coarsened trabecular pattern and sclerosis typical of Paget's disease. 
those clinical studies in which lesions detected by 
scan but not by x-ray were .evaluated by follow-up x-
rays, biopsy, or autopsy, no actual false-positives 
have occurred (20,24,39 ,49 ). 
TABLE 3 
Non-Neoplastic Causes of Posi1ive Bone Scan 
Traumatic 
Fracture 
Slipped epiphysis 
Metabolic 
Paget's 
Renal osteodystrophy 
Hypertrophic pulmonary osteoarthropathy 
Gout 
Rickets 
Inflammatory 
Arthritis (any type) 
Osteomyelitis 
Tendinitis 
Miscellaneous 
Aseptic necrosis 
Osteitis pubis 
Hyperostosis frontalis interna 
Post-thoracotomy 
The Unified Radiologic Approach. Because of the 
already high and ever increasing cost of medical care, 
we need to reassess the manner in which bone scans 
and radiographs are utilized so that the patient may 
benefit from minimum waste and duplication of 
effort. To this end, we have developed a unified 
radiologic approach to the detection of skeletal 
metastases (51 ). An appropriate examination is 
"tailored" individually for each patient according to 
the scheme outlined in Figure 4 which is based on an 
extensive review of the literature as noted above. 
Because of the extensive experience in patients 
with primary neoplasms of breast, lung, and prostate, 
and also lymphoma, it is reasonable to perform the 
bone scan as the primary study in these patients. It 
has even been suggested that the bone scan com-
pletely replace the skeletal survey in the evaluation of 
all patients for skeletal metastases (52). This may 
shortly come to pass; however, reported experience 
with primary neoplasms other than those mentioned 
is not yet great enough. Therefore, we believe that in 
those patients it is still necessary to perform both 
complete examinations. It is much more efficient, 
nevertheless, to perform the scan as the initial study, 
MALL AND HOFFER: BONE SCANNING AND SKELETAL RADIOGRAPHY I 13 
Skeletal Survey 
Skeletal Survey 
& Add itiona l Xroys 
CONSULTATION REQUEST Review 
by Radiologist 
Inte rpretation 
Pelvis Xroy 
Xrays 
Fig 4-Scheme for radiologic examination of patients with suspected pone metastasis. 
even in the latter group. This is because the 
radionuclide bone scan, as generally performed, is an 
evaluation of the entire skeleton whereas the 
radiographic skeletal survey, as generally performed, 
covers only the axial skeleton. Thus, any sites outside 
the axial skeleton which may be positive on the scan 
can be radiographed at the time the skeletal survey i~ 
obtained, thereby eliminating wasted time and effort. 
This approach is feasible only if false-negative, and to 
a lesser extent, false-positive bone scans occur infre-
quently.False-negative scans occur infrequently and 
usually in specific circumstances as described above. 
To further minimize this possibility, however, we 
have incorporated into our approach a radiograph of 
the pelvis even if the scan is normal. As explained 
above, false-positive bone scans are, for practical 
purposes, almost nonexistent. 
The efficacy and practicability of the unified ap-
proach was determined in a trial period during which 
it was applied to all patients referred to the radiology 
department for either radionuclide bone scan or 
radiographic skeletal survey for the detection of 
skeletal metastases. A comparison of the individually 
"tailored" examination actually performed with the 
examination (or examinations) requested by the 
clinical service revealed malutilization of these 
radiologic modalities; that is, superfluous, inadequate 
or inappropriate studies were requested in almost 
half the patients examined (51 ). 
Conclusions. 
I . Technetium-99m-labeled phosphate com-
pounds are currently the agents of choice for radio-
nuclide bone scanning. 
2. Metastatic involvement of bone is most fre-
quently identified by a localized area of increased up-
take. Uncommon signs of skeletal metastasis are a 
localized area of decreased uptake and generalized 
symmetrically increased upta.ke with reduced renal 
excretion. 
3. Radionuclide bone scanning is much more 
sensitive than the radiographic skeletal survey for the 
detection of skeletal metastases. 
4. Since the findings on the bone scan are non-
specific, all abnormal areas should be radiographed 
to determine the nature of the abnormality. 
5. The incorporation of the radionuclide bone 
scan and the radiographic skeletal survey into a single 
unified examination for the detection of skeletal 
metastases, formulated and coordinated by the 
radiologist, is desirable, practicable, and efficacious. 
Table I and Table 2 reprinted with permission from 
Radiology, Vol. 117, No. I. 
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Figure 4 reprinted with permission of Radiology, Vol. 117, 
No. I. 
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